Suppr超能文献

接受利妥昔单抗-CHOP治疗的弥漫性大B细胞淋巴瘤患者中与MYC重排和Myc过表达相关的临床特征、肿瘤生物学及预后

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

作者信息

Xu-Monette Zijun Y, Dabaja Bouthaina S, Wang Xiaoxiao, Tu Meifeng, Manyam Ganiraju C, Tzankov Alexander, Xia Yi, Zhang Li, Sun Ruifang, Visco Carlo, Dybkaer Karen, Yin Lihui, Chiu April, Orazi Attilio, Zu Youli, Bhagat Govind, Richards Kristy L, Hsi Eric D, Choi William W L, van Krieken J Han, Huh Jooryung, Ponzoni Maurilio, Ferreri Andrés J M, Møller Michael B, Parsons Ben M, Zhao Xiaoying, Winter Jane N, Piris Miguel A, McDonnell Timothy J, Miranda Roberto N, Li Yong, Medeiros L Jeffrey, Young Ken H

机构信息

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Mod Pathol. 2015 Dec;28(12):1555-73. doi: 10.1038/modpathol.2015.118. Epub 2015 Nov 6.

Abstract

MYC dysregulation, including MYC gene rearrangement and Myc protein overexpression, is of increasing clinical importance in diffuse large B-cell lymphoma (DLBCL). However, the roles of MYC and the relative importance of rearrangement vs overexpression remain to be refined. Gaining knowledge about the tumor biology associated with MYC dysregulation is important to understand the roles of MYC and MYC-associated biology in lymphomagenesis. In this study, we determined MYC rearrangement status (n=344) and Myc expression (n=535) in a well-characterized DLBCL cohort, individually assessed the clinical and pathobiological features of patients with MYC rearrangement and Myc protein overexpression, and analyzed the prognosis and gene expression profiling signatures associated with these MYC abnormalities in germinal center B-cell-like and activated B-cell-like DLBCL. Our results showed that the prognostic importance of MYC rearrangement vs Myc overexpression is significantly different in germinal center B-cell-like vs activated B-cell-like DLBCL. In germinal center B-cell-like DLBCL, MYC-rearranged germinal center B-cell-like DLBCL patients with Myc overexpression significantly contributed to the clinical, biological, and prognostic characteristics of the overall Myc-overexpressing germinal center B-cell-like DLBCL group. In contrast, in activated B-cell-like DLBCL, the occurrence, clinical and biological features, and prognosis of Myc overexpression were independent of MYC rearrangement. High Myc levels and Myc-independent mechanisms, either tumor cell intrinsic or related to tumor microenvironment, conferred significantly worse survival to MYC-rearranged germinal center B-cell-like DLBCL patients, even among Myc(high)Bcl-2(high) DLBCL patients. This study provides new insight into the tumor biology and prognostic effects associated with MYC dysregulation and suggest that detection of both MYC translocations and evaluation of Myc and Bcl-2 expression is necessary to predict the prognosis of DLBCL patients.

摘要

MYC失调,包括MYC基因重排和Myc蛋白过表达,在弥漫性大B细胞淋巴瘤(DLBCL)中的临床重要性日益增加。然而,MYC的作用以及重排与过表达的相对重要性仍有待明确。了解与MYC失调相关的肿瘤生物学对于理解MYC及MYC相关生物学在淋巴瘤发生中的作用至关重要。在本研究中,我们在一个特征明确的DLBCL队列中确定了MYC重排状态(n = 344)和Myc表达(n = 535),分别评估了MYC重排和Myc蛋白过表达患者的临床和病理生物学特征,并分析了生发中心B细胞样和活化B细胞样DLBCL中与这些MYC异常相关的预后及基因表达谱特征。我们的结果表明,在生发中心B细胞样与活化B细胞样DLBCL中,MYC重排与Myc过表达的预后重要性存在显著差异。在生发中心B细胞样DLBCL中,伴有Myc过表达的MYC重排生发中心B细胞样DLBCL患者对整个Myc过表达生发中心B细胞样DLBCL组的临床、生物学和预后特征有显著贡献。相反,在活化B细胞样DLBCL中,Myc过表达的发生、临床和生物学特征及预后与MYC重排无关。高Myc水平以及肿瘤细胞内在或与肿瘤微环境相关的Myc非依赖性机制,即使在Myc(高)Bcl-2(高) DLBCL患者中,也会使MYC重排生发中心B细胞样DLBCL患者的生存显著变差。本研究为与MYC失调相关的肿瘤生物学及预后影响提供了新的见解,并表明检测MYC易位以及评估Myc和Bcl-2表达对于预测DLBCL患者的预后是必要的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验